Open AccessDoes the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials?
Author(s) -
Vincenzo Serretta,
Cristina Scalici Gesolfo,
Vincenza Alonge,
Giuseppe Cicero,
Marco Moschini,
Renzo Colombo
Publication year - 2015
Publication title -
urologia internationalis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.771
H-Index - 53
eISSN - 1423-0399
pISSN - 0042-1138
DOI - 10.1159/000430501
Subject(s) - medicine , toxicity , regimen , clinical trial , bladder cancer , surgery , cancer
The aim of this study was to analyze the reasons for intravesical BCG interruption in clinical practice. BCG for at least one year is advocated as the best regimen to treat high-risk non-muscle invasive bladder cancer (NMIBC). However, almost 50% of patients don't complete it. Toxicity accounts for 10% of dropouts in international trials.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom